Skip to main content

Hodgkin Lymphoma

Criteria to qualify for study: Drug used in study:
  • Hemoblobin A1C must be ≤ 6.4%
  • Patient must be tested for and be negative for HIV, Hep B & C
  • PLT must be at least 75
  • ANC must be at least 1000
  • Creatinine ≤ 1.5 x ULN or Cr Cl ≥ 50 ml/min

SCRI LYM 90

A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma


Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • Phase 1a Escalation
  • Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75
  • HGB > 10 in absence of transfusion and growth factors for at least 28 days /
  • ECOG 0,1 or 2

Hemref 43 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed of Refractory Hematologic Malignancies